Crestone Pharma’s Post

CRS3123 is a small molecule protein synthesis inhibitor that acts on the novel target methionyl-tRNA synthetase (MetRS). CRS3123 has numerous potential advantages over current CDI therapies. Learn more about C. difficile Infection (CDI) and the Phase 2 study of CRS3123 here: https://bit.ly/3zhg5Kb

Anti-body coated RBCs are detected in direct coombs. First wash the blood sample that is contained EDTA ( as anti-coagulant ) three times with normal saline, decant to a dry cell botton and make suspension 2-5%. Add two drops of anti-human globulin (coombs serum ) to one drop of suspension then centrifuge it. Now you can observe the result. Positive direct coombs caused by: * Hemolytic transfusion reactions. * Autoantibodies to intrinsic RBC antigens. * Hemolytic disease of the newborn. * Drug-induced antibodies. * Passively acquired alloantibodies, such as from donor plasma or immunoglobulin. * Nonspecifically adsorbed proteins.

Happy 2025! Let's start the year by learning about monoclonal antibodies! Sanofi is pioneering the future of medicine with #MonoclonalAntibody (mAb), a key technology of our #Immunoscience ambition. 🔬 Our latest video highlights how mAb technology is creating breakthroughs in treating chronic inflammatory diseases and holds promise for preventing infectious diseases like bronchiolitis caused by Respiratory Syncytial Virus #RSV 🦠

Thyroid peroxidase (TPO) is a critical enzyme involved in thyroid hormone synthesis. TPO is well known to be the principal antigen against which antibodies are directed in autoimmune thyroid disease. Elevated serum titer of anti-TPO antibody is found in 90% cases of Hashimoto’s thyroiditis. In Graves’ disease, 70% of patients have an elevated titer. Learn more about the testing with Medical Database. https://lnkd.in/de7MvM77 #medicaldatabase

Ophthopedia Update:Paradoxical keratitis and dermatitis following adalimumab treatment: Anti-tumor necrosis factor (TNF) monoclonal antibodies are an important tool in the management of rheumatologic disease. However, paradoxical inflammation can be precipitated by their use. This case report describes the development of keratitis and dermatitis following adalimumab treatment for chronic recurrent multifocal osteomyelitis in a 6-year-old girl. The keratitis and dermatitis subsided once topical steroids were started and the adalimumab was held. #Ophthalmology #Eye #Ophthotwitter

HEPCITAJ® #SofosbuvirTablets, Film-coated 400 mg contains the active substance sofosbuvir which is given to treat #hepatitis C virus infection in adults & adolescents from the age of 12 years up to the age of 18 years. Sofosbuvir Tablets, Film-coated 400 mg is always taken with other medicines. Always take this medicine exactly as your health care provider has told you. Check with your health care provider if you are not sure. Ledipasvir and sofosbuvir are both direct-acting antiviral agents. Sofosbuvir is a liver-targeted nucleotide prodrug of the active triphosphate GS-461203, which has been approved for use in HCV genotypes 1–4. It works as an inhibitor of the #HCV NS5B RNA-dependent RNA polymerase, which acts as a chain terminator. It works by reducing the amount of hepatitis C virus in your body, which may help your liver recover. 📝#HepatitisC is a virus that infects the liver. #TajPharma

💡 Trellis Bioscience Inc. won $297,917 from the Department of Health and Human Services' National Institutes of Health. The award is for conducting a phase 1 safety trial in healthy adult volunteers for TRL1068, a native human monoclonal antibody that disrupts biofilm and enhances the bactericidal activity of conventional antibiotics. The goal is to develop an inhaled therapeutic to treat bronchial infections. #SBIR #STTR #AntibioticResistance #Biofilm 📊 The project builds upon prior SBIR funding that demonstrated efficacy in five rodent models and a clinical development for patients with prosthetic joint infection. 📅 The award is a cooperative agreement that lasts for 0.42 years, starting from July 18, 2024, and ending on December 31, 2024.

Anti-ribosomal P protein antibody (anti-#RibP) was identified in 1965 and recognize a common C-terminal 22-amino-acid (C22) sequence shared by #ribosomal acidic phosphoproteins (P1, P2 and P0). The presence of anti-RibP is particular to systemic #lupus erythematosus (#SLE) and is often accompanied by dsDNA antibodies. Anti-RibP titres are quantitatively correlated with several clinical markers, cytokines, and tryptophan metabolites in SLE, and are independently associated with the prevalence of skin rash and the initial prednisolone dose. Of the IgG subclasses, anti-RibP IgG3 contributed the most to disease activity in SLE. 🔗https://lnkd.in/dptchsbG

The BRUCELLACAPT® Test by VIRCELL S.L. is specifically developed to address the urgent need for accurate and quick diagnosis of brucellosis, a contagious infection caused by the Brucella bacterium. Brucellosis can lead to severe health complications if not promptly identified and treated. Traditional antibody tests often involve multiple steps and extended processing times, which can delay diagnosis and treatment. The Brucella Test from Vircell offers a streamlined alternative, enabling reliable detection of Brucella antibodies in human serum and plasma with greater efficiency. Designed to run seamlessly on the Virclia® Lotus analyser, the Brucella Test comes in both IgG and IgM assays, providing comprehensive insights into past and current infections. This indirect chemiluminescent immunoassay features a convenient monotest format with ready-to-use reagents, simplifying the testing process and reducing preparation time. The automated protocol ensures rapid results, while each monodose contains a calibrator and a negative control to guarantee the accuracy of every individual sample. Additionally, the ability to pipette directly from primary sample tubes without further manipulation enhances flexibility and ease of handling for clinical laboratories. By incorporating the Brucella Test into your diagnostic procedures, laboratories can perform Brucella antibody testing more efficiently, facilitating quicker decision-making and improving patient management. #CLIA #Brucella #Brucellosis #MedicalDiagnostics #HealthcareInnovation #MedicalDevices #BabirusEgypt